Jeff Johnson
Stock Analyst at Baird
(4.61)
# 239
Out of 5,005 analysts
148
Total ratings
56.44%
Success rate
28.47%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $112 → $90 | $67.05 | +34.23% | 15 | Sep 26, 2025 | |
| COO The Cooper Companies | Maintains: Outperform | $97 → $85 | $70.46 | +20.64% | 18 | Aug 28, 2025 | |
| ALC Alcon | Maintains: Outperform | $108 → $95 | $77.38 | +22.77% | 10 | Aug 21, 2025 | |
| BBNX Beta Bionics | Maintains: Neutral | $15 → $17 | $22.26 | -23.63% | 2 | Jul 30, 2025 | |
| HSIC Henry Schein | Downgrades: Neutral | $82 → $72 | $67.03 | +7.41% | 10 | Jul 14, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $20.85 | +10.31% | 10 | May 27, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $100.78 | +14.11% | 14 | May 6, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $14.71 | +63.15% | 16 | May 1, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $370.50 | +9.31% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $132.17 | +108.82% | 18 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $309.12 | -23.01% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $32.02 | +118.61% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $15.15 | +302.64% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $13.19 | +407.96% | 6 | Feb 18, 2022 |
DexCom
Sep 26, 2025
Maintains: Outperform
Price Target: $112 → $90
Current: $67.05
Upside: +34.23%
The Cooper Companies
Aug 28, 2025
Maintains: Outperform
Price Target: $97 → $85
Current: $70.46
Upside: +20.64%
Alcon
Aug 21, 2025
Maintains: Outperform
Price Target: $108 → $95
Current: $77.38
Upside: +22.77%
Beta Bionics
Jul 30, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $22.26
Upside: -23.63%
Henry Schein
Jul 14, 2025
Downgrades: Neutral
Price Target: $82 → $72
Current: $67.03
Upside: +7.41%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $20.85
Upside: +10.31%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $100.78
Upside: +14.11%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $14.71
Upside: +63.15%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $370.50
Upside: +9.31%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $132.17
Upside: +108.82%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $309.12
Upside: -23.01%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $32.02
Upside: +118.61%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $15.15
Upside: +302.64%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $13.19
Upside: +407.96%